Fosavance 70 mg/5600 IU Tablet is a combination medication containing Alendronic Acid 70 mg and Vitamin D3 5600 IU, primarily used to treat and prevent osteoporosis in postmenopausal women and other individuals at high risk of fractures. Alendronic Acid belongs to the bisphosphonate class, which works by inhibiting bone resorption, thereby increasing bone mineral density and reducing the likelihood of fractures, particularly in the spine and hip. Vitamin D3 plays a crucial role in calcium absorption and bone health, ensuring optimal mineralization and supporting the therapeutic effects of Alendronic Acid. Fosavance is typically prescribed once weekly and should be taken on an empty stomach with a full glass of water, at least 30 minutes before the first food or drink of the day, to maximize absorption and minimize gastrointestinal side effects. Patients are advised to remain upright for at least 30 minutes post-dose to prevent esophageal irritation. Common side effects may include gastrointestinal discomfort, such as heartburn or nausea, but these are generally mild and transient. Fosavance is an effective treatment option for improving bone strength and reducing fracture risk, contributing to enhanced quality of life in individuals with osteoporosis. Regular medical follow-up is recommended to monitor treatment response and ensure safety.